卡培他滨联合草酸铂和紫杉醇一线治疗晚期或转移性胃癌  

An Observation Study of Paclitaxel/Oxaliplatin/Capecitabine Regimen as First-line Therapy for Patients with Advanced Gastric Cancer

作　　者：胡国勇[1] 胡娟[2] 杨建国[1] 丁岩冰[1] 吴健[1] 肖炜明[1] 

机构地区：[1]扬州市第一人民医院消化内科,江苏扬州225001 [2]扬州市第一人民医院检验科

出　　处：《咸宁学院学报（医学版）》2006年第6期487-489,共3页Journal of Xianning Univarsity(medical Sciences)

摘　　要：目的评估卡培他滨联合草酸铂和紫杉醇一线治疗晚期或转移性胃癌的疗效和毒副反应。方法全组36例患者，采用卡培他滨1250mg／（m^2·d），连用14d；紫杉醇90mg／（m^2·d）静滴，第1、8d；草酸铂100mg／（m^2·d）静滴，第1、8d；21d为1周期，用药2～6个周期后进行评估。结果垒组34例可评价，获得CR1例，PR21例，SD8例，PD3例，有效率（CR＋PR）为69．5%，中位TTP为9个月（2～17个月），中位生存时间16个月（2-38个月）。主要毒副反应为胃肠反应和骨髓抑制．多为Ⅰ～Ⅱ度毒性反应，Ⅲ～Ⅳ度毒性反应主要为口腔炎、恶心呕吐、白细胞和血小板降低。所有患者均无化疗相关性死亡。结论卡培他滨联合草酸铂和紫杉醇一线治疗晚期胃癌患者近期疗效较好，不良反应可以耐受，值得临床推广。Objective To evaluate the objective response rate and toxicity of paclitaxel/oxaliplatin/capecitabine regimen as first-line therapy for patients with advanced gastric cancer. Methods 36 patients with advanced gastric cancer were administrated with intravenous paclitaxel 90 mg · m^2 （d1 , d8 ） , intravenous oxaliplatin 100 mg· m^2 （d1 , d8） , and oral capecitabine 1250 mg · m^2 twice daily （dl- 14） in a 21-day cycle of therapy for 2-6 cycles. Results 34 patients were assessable for efficacy and toxicity. One patient achieved a complete response and 21 patients had partial responses, an overall response rate was 69.5 %. The median TTP for all was 9 months（range 2-17 months）. The median overall survival was 16 months（range 2-38 months）. The most common adverse effects were myelosuppression and gastrointestinal response. There were no chemotherapy-related deaths. Conclusion The combination of capecitabine and oxaliplatin/paclitaxel is effective and well tolerated as first-line therapy for patients with advanced gastric cancer.

关 键 词：胃癌 卡培他滨 草酸铂 紫杉醇 化疗 

分 类 号：R730.53[医药卫生—肿瘤]